EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 95 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Cancer in My Community: Expanding Access to Genetic Testing in Mexico September 1, 2020 Breast Cancer Death Rates Will Rise in Elderly EU Patients but... March 12, 2025 FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced... July 19, 2024 Greater Severity of Adverse Events in Women Across Multiple Anticancer Treatment... February 11, 2022 Load more HOT NEWS EMA Recommends Extension of Indications for Durvalumab Two Drugs Work Together to Block ‘Master Regulator’ of Breast, Other... Educators Raise Money in Memory of Teacher Who Dedicated Herself to... Jaw Problems Linked to Bone-Modifying Drugs Not as Rare as Once...
